Orlando Rangel
General Practice · Tampa, FLNPI 1942379466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 25.2% of the total. Reporting peaked in 2019 at $817 and has fallen 85.1% since, to $122 in 2024. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$787
- Novo Nordisk$711
- Boehringer Ingelheim$276
- GSK$214
- Johnson & Johnson$196
- Lilly USA, LLC$177
- plus $756 from 16 others
Across 41 payments — averaging $689.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$22K
- Akebia Therapeutics Inc$5K
- Biogen$2K
What the payments were for
- Food & beverage$3,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $787 |
| Novo Nordisk | 30 | $711 |
| Boehringer Ingelheim | 7 | $276 |
| GSK | 7 | $214 |
| Johnson & Johnson | 6 | $196 |
| Lilly USA, LLC | 4 | $177 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Pfizer | 6 | $100 |
| Abbott | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $67 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Novartis | 3 | $55 |
| Mylan Specialty L.p. | 2 | $50 |
| Bayer | 3 | $45 |
| AbbVie | 2 | $41 |
| Amgen | 2 | $29 |
| Lifescan, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Biogen | 1 | $17 |
| Lundbeck LLC | 1 | $13 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,117 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 76 | $63,682 |
| EliquisApixaban | 49 | $42,783 |
| FarxigaDapagliflozin Propanediol | 57 | $42,173 |
| TrulicityDulaglutide | 28 | $31,556 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 46 | $29,146 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $9,667 |
| VascepaIcosapent Ethyl | 18 | $9,410 |
| BrilintaTicagrelor | 11 | $5,583 |
| Sucralfate | 35 | $5,070 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 102 | $2,863 |
| Atorvastatin Calcium | 358 | $2,461 |
| Levothyroxine Sodium | 212 | $2,049 |
| Rosuvastatin Calcium | 190 | $1,939 |
| Losartan Potassium | 204 | $1,920 |
| Ventolin HfaAlbuterol Sulfate | 31 | $1,875 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $276 | $92,828122 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $787 | $57,423101 claims |
| PfizerEliquis | $100 | $42,78349 claims |
| Lilly USA, LLCTrulicity | $177 | $31,55628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Tampa
- Sarah JockinTampa$308K
- Jeffrey HuntTampa$78K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.